Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table provides information about disaggregated revenue by major product line and primary geographic market (in thousands):

	Three Months Ended March 31, 2018
	Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	2,686	$	1,485	$	503	$	4,674
Consumables	6,160		2,377		820		9,357
In vitro diagnostic kits	681		1,397		88		2,166
Total product revenue	9,527		5,259		1,411		16,197
Service revenue	1,261		499		88		1,848
Total product and service revenue	10,788		5,758		1,499		18,045
Collaboration revenue	5,040		—		—		5,040
Total revenues	$	15,828	$	5,758	$	1,499	$	23,085

	Three Months Ended March 31, 2017
	Americas		Europe and Middle East		Asia Pacific		Total
Product revenue:
Instruments	$	2,815	$	1,186	$	469	$	4,470
Consumables	5,596		2,114		882		8,592
In vitro diagnostic kits	481		916		42		1,439
Total product revenue	8,892		4,216		1,393		14,501
Service revenue	1,021		199		44		1,264
Total product and service revenue	9,913		4,415		1,437		15,765
Collaboration revenue	2,298		—		—		2,298
Total revenues	$	12,211	$	4,415	$	1,437	$	18,063

Schedule of New Accounting Pronouncements and Changes in Accounting Principles

In accordance with the new revenue guidance, the disclosure of the impact of adoption of this new standard to our condensed consolidated statements of income and balance sheets was as follows:

	Three months ended March 31, 2018
	Impact of changes in accounting standard
(in thousands, except per share amounts)	As Reported			Amounts under previous revenue standard			Effect of Change
Revenue:
Product and service	$	18,045		$	17,807		$	238
Collaboration	5,040			5,040			—
Total revenue	23,085			22,847			238
Net loss	$	(19,202	)	$	(19,440	)	$	238
Net loss per share - basic and diluted	$	(0.75	)	$	(0.76	)	$	0.01

	March 31, 2018
(in thousands)	As Reported			Balances under previous revenue standard			Effect of Change
Liabilities:
Deferred revenue, current portion	$	10,312		$	9,796		$	516
Stockholders' equity
Accumulated deficit	(333,058		)	(332,542		)	(516		)